SpliceBio has closed a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventures. There was also participation from Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners. The funding will be used to advance […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!